EGFR and non-small cell lung carcinoma: The Phase III randomized controlled trial SINDAS(NCT 02893332) (23) included patients with synchronous OM-NSCLC with EGFR mutations, ≤ 5 metastatic lesions, with participants randomly assigned to receive first- generation tyrosine kinase inhibitors (TKIs) alone or upfront SABR plus TKIs for all disease sites.